Which version of Venetoclax is better?

Venetoclax/Venetoclax (Venetoclax) is a targeted therapy drug mainly used to treat chronic lymphocytic leukemia (CLL) and related hematological malignancies. It was jointly developed by the American pharmaceutical company AbbVie and Genentech, and was approved for marketing by the U.S. Food and Drug Administration (FDA) in 2016.

Venetoclax/Venetoclax can be divided into original drugs and generic drugs. The price of the original drug is much higher, while the price of foreign generic drugs is relatively much cheaper. The ingredients of the two drugs are basically the same, and the specific decision is based on the patient's own financial ability.

Venetoclax/Venetoclax has been launched in China and has been included in medical insurance, and patients can purchase it domestically. Specifications: 100mg*14tablets and the price is around 5,000yuan. Please consult the local hospital pharmacy for specific prices. There are original drugs and generic drugs abroad. The Turkish version of Venetoclax/Venetoclaxoriginal drug on the market overseas, specification: 100mg*112 tablets, costs about 10,000 per box. Foreign generic drugs are relatively cheaper. For example, the generic drugs sold in Laos and Bangladesh are priced at about more than 4,000 yuan for 100mg*120 tablets. The ingredients of original drugs and generic drugs are basically the same.

Venetoclax/Venetoclax is unique in its mechanism of action. It is an oral drug that specifically inhibits B cell lymphocytes. Tumor/Leukemia-2 (BCL-2) protein to exert its therapeutic effect. BCL-2The protein is an anti-apoptotic protein. Overexpression of BCL-2 can cause certain cancer cells to resist apoptotic signals, thereby promoting the abnormal proliferation of these cancer cells. By inhibiting BCL-2, venetoclax can break this anti-apoptotic mechanism and guide cancer cells to undergo programmed cell death.

Venetoclax/Venetoclax is mainly used to treat CLL, especially for those patients who carry chromosome 17 deletion, which is a more complex CLL subtype. In addition, Venetoclax/Venetoclax has also shown good efficacy in the treatment of some non-Hodgkin lymphomas.